Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
G Michael FelkerScott D SolomonMarco MetraJohn J V McmurrayRafael DiazBrian ClaggettDavid E LanfearHans VandekerckhoveTor Biering-SørensenRenato D LopesAlexandra Arias-MendozaShin-Ichi MomomuraRamon CorbalanFelix J A RamiresFaiez ZannadStephen B HeitnerPunag H DivanjiStuart KupferFady I MalikJohn R TeerlinkPublished in: Journal of cardiac failure (2024)
In a cohort of patients with HFrEF, baseline cTnI concentrations were strongly associated with adverse clinical outcomes. Although cTnI concentrations were higher in patients treated with omecamtiv mecarbil, we did not find a differential effect of omecamtiv mecarbil on either safety or efficacy based on baseline cTnI status or change in cTnI.
Keyphrases